Moderna Inc (NASDAQ:MRNA) has dosed the first participant in the Phase 2 study of its omicron-specific bivalent booster candidate (mRNA-1273.214).
The vaccine candidate combines Moderna's omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273).
The extension of an earlier study will evaluate mRNA-1273.214 as a single booster dose in adults who previously received the two-dose primary series of mRNA-1273 and a 50 µg booster dose of mRNA-1273 with the booster dose being at least three months ago.
Also See: Moderna Plans Vaccines Against 15 Pathogens With Future Pandemic Potential.
Moderna expects to enroll approximately 375 participants.
The Company is also evaluating its omicron-specific booster candidate (mRNA-1273.529) in a Phase 2 study in the U.S.
Separately, Moderna is evaluating mRNA-1273.529 in a Phase 3 study in the U.K., collaborating with the National Institute for Health Research. Dosing with mRNA-1273.214 will begin soon.
Price Action: MRNA shares are down 3.53% at $137.46 during the market session on the last check Thursday.
Photo by mufidpwt via Pixaby
